



New Options for HER2+ Breast Cancer:

Building on Success

Sunday, 21 October 2018
13.00 – 14.30

ICM – Room 1
Messe Munich
Munich, Germany

Chair

Hope S. Rugo, MD, FASCO
University of California San Francisco
Helen Diller Family Comprehensive
Cancer Center
San Francisco, California, United States

Faculty

John Crown, MD, FRCPI
St. Vincent's University Hospital
Dublin, Ireland

Miguel Martín, MD, PhD
Complutense University
Hospital General Universitario
Gregorio Marañón
Madrid, Spain

Michael Untch, MD, PhD
HELIOS Klinikum Berlin-Buch
Berlin, Germany

Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Agenda

- 13.00 Welcome and introduction
Hope S. Rugo, MD, FASCO
- 13.02 HER2+ breast cancer:
Clinical scenarios and
treatment recommendations
Hope S. Rugo, MD, FASCO
- 13.10 The changing natural history of
HER2+ breast cancer
Michael Untch, MD, PhD
- 13.25 Preventing recurrent disease:
How can we bring new adjuvant
therapeutic opportunities to
the clinic?
Miguel Martín, MD, PhD
- 13.45 HER2+ metastatic breast cancer
in 2018: Is this as good as it gets?
John Crown, MD, FRCPI
- 14.05 Panel discussion
All faculty
- 14.20 Bringing it all together:
Clinical application of
recent developments
All faculty
- 14.28 prIME Points™
Hope S. Rugo, MD, FASCO
- 14.30 Adjourn



Better Decisions Start With My prIME

Access hundreds of live events and online activities that help advance your practice and improve clinical outcomes.